Literature DB >> 20590833

Development of PET radiopharmaceuticals and their clinical applications at the Positron Medical Center.

Kiichi Ishiwata1, Yuichi Kimura, Keiichi Oda, Kenji Ishii, Muneyuki Sakata, Keiichi Kawasaki, Tadashi Nariai, Yukihisa Suzuki, Kenji Ishibashi, Masahiro Mishina, Masaya Hashimoto, Masatomo Ishikawa, Jun Toyohara.   

Abstract

The Positron Medical Center has developed a large number of radiopharmaceuticals and 36 radiopharmaceuticals have been approved for clinical use for studying aging and geriatric diseases, especially brain functions. Positron emission tomography (PET) has been used to provide a highly advanced PET-based diagnosis. The current status of the development of radiopharmaceuticals, and representative clinical and methodological results are reviewed.

Mesh：

Substances：

Year:  2010        PMID： 20590833     DOI： 10.1111/j.1447-0594.2010.00594.x

Source DB:  PubMed          Journal:  Geriatr Gerontol Int        ISSN： 1447-0594            Impact factor:   2.730


  3 in total

1.  Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients.

Authors:  Masahiro Mishina; Kiichi Ishiwata; Mika Naganawa; Yuichi Kimura; Shin Kitamura; Masahiko Suzuki; Masaya Hashimoto; Kenji Ishibashi; Keiichi Oda; Muneyuki Sakata; Makoto Hamamoto; Shiro Kobayashi; Yasuo Katayama; Kenji Ishii
Journal:  PLoS One       Date:  2011-02-28       Impact factor: 3.240

2.  Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for Imaging α-Synuclein.

Authors:  Xiang Zhang; Hongjun Jin; Prashanth K Padakanti; Junfeng Li; Hao Yang; Jinda Fan; Robert H Mach; Paul Kotzbauer; Zhude Tu
Journal:  Appl Sci (Basel)       Date:  2014-03-17       Impact factor: 2.679

Review 3.  In Vivo Positron Emission Tomography Imaging of Adenosine A2A Receptors.

Authors:  Meng-Juan Sun; Fang Liu; Ya-Fei Zhao; Xiao-Ai Wu
Journal:  Front Pharmacol       Date:  2020-11-26       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.